Propanc Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Net Income	-18.36	-58.92	-1.82	-2.66	-2.66	-2.03
Depreciation & Amortization	0	-	0	0	0	0
Stock-Based Compensation	11.13	55.97	-	0.14	0.39	0.21
Other Adjustments	-0.1	1.41	0.47	0.94	0.67	0.23
Changes in Accounts Payable	-0.27	0.19	0.24	0.08	0.02	0.18
Changes in Accrued Expenses	0.28	0.97	0.34	0.41	0.16	0.27
Changes in Other Operating Activities	-0.09	-0.02	-0.16	-0.02	-0.01	-0.01
Operating Cash Flow	-4.17	-0.41	-0.94	-1.11	-1.44	-1.15
Capital Expenditures	-0	-	-	-	-	-
Investing Cash Flow	-0	-	-	-	-	-
Long-Term Debt Issued	0.55	0.89	1.06	0.59	0.77	0.33
Long-Term Debt Repaid	-1.05	-0.13	-0.14	-	-	-0.04
Net Long-Term Debt Issued (Repaid)	-0.5	0.76	0.92	0.59	0.77	0.28
Issuance of Common Stock	3.31	-	0.02	0.52	0.72	0.78
Net Common Stock Issued (Repurchased)	3.31	-	0.02	0.52	0.72	0.78
Issuance of Preferred Stock	0.48	-	-	-	-	-
Net Preferred Stock Issued (Repurchased)	0.48	-	-	-	-	-
Other Financing Activities	-0.2	-0.26	-	-	-	-
Financing Cash Flow	4.55	0.49	0.94	1.11	1.49	1.06
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.02	-0.09	0	-0	-0.05	0.02
Net Cash Flow	0.39	-0.01	0.01	0.01	0	-0.06
Free Cash Flow	-4.18	-0.41	-0.94	-1.11	-1.44	-1.15
Free Cash Flow Per Share	-6.99	-2.55	-16498.20	-953459.00	-31581500.00	-566474000.00
Levered Free Cash Flow	-19.88	-57.03	-0.68	-2.06	-2.42	-1.69
Unlevered Free Cash Flow	-18.46	-56.14	-1.02	-1.22	-1.78	-1.28